Executive Series: Deciding to Go Commercial
Campbell Alliance is collaborating with BayBio to offer a CEO Breakfast Series to address critical issues facing the current generation of C-suite executives in the pharmaceutical and biotech industries. The next event in this series will examine the key decision points for emerging companies to consider when deciding if and when to build internal commercial capabilities.
As an emerging pharmaceutical or biotech company develops its first few assets, its leaders face a key strategic question: Do they license their assets out to larger partners at some appropriate point in development, or do they take the somewhat riskier (but potentially more lucrative) approach of becoming a fully integrated pharmaceutical company and develop an internal commercialization capability? While strong arguments can be made in favor of either strategy, there are several considerations to make when deciding which approach may be best for a company to take. At any growth-oriented company, resources are far from endless, so trade-offs will need to be measured and made. The cost of building commercial capabilities must be considered along with the specific functions to be built and the roles each function will serve. The complexity of the market—or markets in some cases—in which a company might enter should be considered as well. Regardless of the path a company decides to follow, timing is critical. In most cases, there is both a limited financing window and a limited partnering window in order to move forward. Any decision that is made may impact not only the first asset to go to market, but the resources available to advance the remaining assets in a company’s portfolio, as well.
In this session, participants will discuss the pros and cons of building an internal commercial capability, as well as a possible framework that CEOs can use for evaluating their strategic options.
Director, Campbell Alliance
Senior Engagement Manager, Campbell Alliance
|What:||Executive Series: Deciding to Go Commercial|
|When:||Tuesday, December 11, 2012
Breakfast and Networking:
7:30AM – 8:00AM
8:00AM – 9:00AM
|Where:||OncoMed Pharmaceuticals, Inc.
800 Chesapeake Dr.
Redwood City, CA 94063-4748
|Attire:||Business Attire Suggested|
|Attendance:||RSVP by December 9 is required
No on-site registrations accepted
Open to C-Suite Executives of
Life Sciences Companies Only.
|Cost:||BayBio Members – FREE
Non-Members – $75.00